Verastem Oncology Reports Q3 Revenue and Outlines Long-Term Funding Strategy
Verastem Oncology (VSTM) reported net product revenue of $24 million for the recent period, driven by its commercial business activities. Management expressed optimism regarding the progress of their VS-7375 development program and overall commercial operations. The company expects to secure financing in October alongside anticipated co-pack revenue. These capital inflows are projected to extend Verastem's operational runway into the first half of 2028, providing significant long-term stability for its ongoing clinical and commercial initiatives.
Topics: biotechnology earnings revenue